BioNTech SE has announced its agreement to acquire CureVac NV, a fellow pharmaceutical company and former Covid vaccine competitor, for approximately $1.25 billion in an all-stock transaction. This strategic acquisition aims to fortify BioNTech’s rapidly expanding oncology division.
Under the terms of the agreement, shareholders of CureVac are poised to receive around $5.46 in BioNTech shares for each CureVac share they own. This offer signifies a substantial 34% premium on the closing price of CureVac shares the day prior to the announcement.
Upon the completion of the transaction, it is anticipated that CureVac shareholders will collectively hold a stake ranging from 4% to 6% in BioNTech. The backdrop to this acquisition is a longstanding, competitive history between the two companies, magnified during the intense development race for a Covid vaccine. BioNTech emerged victorious in this race, largely due to its successful partnership with Pfizer.
As BioNTech bolsters its position within the oncology sector, this deal marks a notable step in its strategic direction post-pandemic. For additional details on the acquisition, visit the Bloomberg article.